540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors

MLA

James L. Gulley, et al. “540 Baseline MTOR Transcriptional Signatures in CD8 T Cells Are Associated with Immune-Related Adverse Events but Not Anti-Tumor Responses in Patients Receiving Immune Checkpoint Inhibitors.” Journal for ImmunoTherapy of Cancer, vol. 9, Nov. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7cf01bbf2f32c1346e20a81e790ead3e&authtype=sso&custid=ns315887.

APA

James L. Gulley, Matthew P. Mulé, Chen Zhao, Andrew L. Mammen, Jinguo Chen, Arun Rajan, Iago Pinal Fernandez, John S. Tsang, Jeffrey Schlom, Andrew J. Martins, & Renee N. Donahue. (2021). 540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer, 9.

Chicago

James L. Gulley, Matthew P. Mulé, Chen Zhao, Andrew L. Mammen, Jinguo Chen, Arun Rajan, Iago Pinal Fernandez, et al. 2021. “540 Baseline MTOR Transcriptional Signatures in CD8 T Cells Are Associated with Immune-Related Adverse Events but Not Anti-Tumor Responses in Patients Receiving Immune Checkpoint Inhibitors.” Journal for ImmunoTherapy of Cancer 9 (November). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7cf01bbf2f32c1346e20a81e790ead3e&authtype=sso&custid=ns315887.